{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:42:32Z","timestamp":1788309752122,"version":"build-2803163510"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,6,30]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate patient characteristics predictive of response to secukinumab in patients with psoriatic arthritis (PsA) with axial manifestations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a post-hoc analysis from the MAXIMISE trial (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02721966\">NCT02721966<\/jats:ext-link>) in patients with PsA and axial manifestations, we tested the hypothesis that the OR of the effect of treatment on the primary endpoint of the trial (Assessment of SpondyloArthritis international Society (ASAS) 20 responder status at week 12) would be different depending on 12 prespecified predictor variables. We applied a two-model logistic regression approach, a main effects and an interaction model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The OR (95%\u2009CI) for ASAS20 response for the presence of nail dystrophy was 3.2 (95% CI 0.93 to 10.99) in the secukinumab 150\u2009mg group and 5.0 (95% CI 1.47 to 17.19) in the secukinumab 300\u2009mg group compared with the placebo group (p=0.029). Odds of being a responder were similar in men and women in the secukinumab groups, though men fared worse than women in the placebo group (p=0.039). Current smokers were less likely to be ASAS20 responders compared with never smokers regardless of the treatment group (p=0.589).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Nail dystrophy was identified as a predictor of response to secukinumab in patients with PsA with axial manifestations in the MAXIMISE trial. These findings may be explained by the nail-entheseal concept as part of the axial phenotype in PsA .<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002303","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T11:45:43Z","timestamp":1658144743000},"page":"e002303","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02721966","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02721966","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Pournara","sequence":"additional","affiliation":[{"name":"Immunology, Hepatology and Dermatology, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[{"name":"Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"},{"name":"Rheumatology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, AP-HP.Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Swedish Medical Center, Providence St Joseph Health and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"White","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eamonn","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Novartis Ireland Limited, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schulz","sequence":"additional","affiliation":[{"name":"Immunology, Hepatology and Dermatology, Novartis Pharma AG, Basel, Basel-Stadt, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"Section of Musculoskeletal Disease, NIHR Leeds Biomedical Research Centre, LTHT and LIRMM, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C","family":"Coates","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"2025090312213790000_8.2.e002303.1","first-page":"S31","article-title":"The involvement of the spine in psoriatic arthritis","volume":"33","author":"Baraliakos","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312213790000_8.2.e002303.2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41584-018-0006-8","article-title":"Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison","volume":"14","author":"Feld","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025090312213790000_8.2.e002303.3","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20017"},{"key":"2025090312213790000_8.2.e002303.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171094"},{"key":"2025090312213790000_8.2.e002303.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808"},{"key":"2025090312213790000_8.2.e002303.6","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17-1-65"},{"key":"2025090312213790000_8.2.e002303.7","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa005","article-title":"Applied machine learning and artificial intelligence in rheumatology","volume":"4","author":"H\u00fcgle","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025090312213790000_8.2.e002303.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-019-1864-9","article-title":"Are innovation and new technologies in precision medicine paving a new era in patients centric care?","volume":"17","author":"Seyhan","year":"2019","journal-title":"J Transl Med"},{"key":"2025090312213790000_8.2.e002303.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l886"},{"key":"2025090312213790000_8.2.e002303.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c117"},{"key":"2025090312213790000_8.2.e002303.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090312213790000_8.2.e002303.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7055.486"},{"key":"2025090312213790000_8.2.e002303.13","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1296"},{"key":"2025090312213790000_8.2.e002303.14","doi-asserted-by":"crossref","unstructured":"Harrell FE . Regression modeling strategies: with applications to linear models, logistic and ordinal regression, and survival analysis. 2edition. Springer: Cham, 2015.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"2025090312213790000_8.2.e002303.15","doi-asserted-by":"publisher","DOI":"10.1159\/000182250"},{"key":"2025090312213790000_8.2.e002303.16","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-04926-7","article-title":"Correction to: the ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions","volume":"39","author":"Idolazzi","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090312213790000_8.2.e002303.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel214"},{"key":"2025090312213790000_8.2.e002303.18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091059"},{"key":"2025090312213790000_8.2.e002303.19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/1744666X.2019.1543591","article-title":"The relationship between smoking, psoriasis and psoriatic arthritis","volume":"15","author":"Pezzolo","year":"2019","journal-title":"Expert Rev Clin Immunol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:21:45Z","timestamp":1756927305000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,7,18]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/rmdopen-2022-002303"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002303","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}